Skip to main content
. 2018 Aug 2;8:11631. doi: 10.1038/s41598-018-30100-w

Figure 1.

Figure 1

Detection of ctDNA in pretreatment plasma samples from 17 pancreatic cancer patients. The top panel summarizes the mutations detected in the 17 patients based on method (i.e., MP/KRAS, MP/FNA, and MP/TR). While interrogation of KRAS hotspots (MP/KRAS) detected ctDNA from 10 patients, analyses of variants detected from FNA samples (MP/FNA) and broad genomic target regions (MP/TR) detected tumor variants in 12 and 15 plasma samples, respectively. The oncoprint chart presents the MFNA and MP/TR at the gene level. If a variant was detected in both the MFNA and MP/TR, the variant also corresponded with MP/FNA. The number of affected genes for each patient was plotted at the bottom of the chart. The number of samples that harbored a mutation in each gene is plotted on the right side of the chart. Two * and four † independent mutations in PDGFRB and ATM were detected in the P43 FNA and plasma samples, respectively.